Nachrichten zur Abbvie Inc. Aktie

AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?

AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk profiles, and…

AbbVie Aktie springt 6%: Milliarden-Übernahme soll Skyrizi absichern

Bad Marienberg (www.aktiencheck.de) - Die AbbVie-Aktie hat Anlegern einen bemerkenswerten Handelstag beschert. Mit einem Kurssprung von 6,25% auf 230,01 USD…

Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer

On June 22, 2026, Apogee Therapeutics shares surged as investors reacted to AbbVies proposed acquisition terms.…

AbbVie Inc. (ABBV) M&A Call Transcript

…

SpaceX’s Big AI Bond Bet | Open Interest 6/22/2026

Get a jump start on the US trading day with Matt Miller and Dani Burger on "Bloomberg Open Interest." Stocks…

Truist reiterates Kymera stock Buy rating after AbbVie deal

Truist reiterates Kymera stock Buy rating after AbbVie deal…

The Clubs top 10 things to watch in the stock market Monday

Abbvie makes a move in M&A, and SpaceX is started with a hold rating at KeyBanc.…

AbbVie to acquire Apogee Therapeutics in $10.9B deal

Abbvie Inc (NYSE:ABBV) announced that it will acquire Apogee Therapeutics (NASDAQ:APGE) in an all-cash transaction valued at approximately $10.9 billion,...…

AbbVie vor Milliarden-Zukauf von Apogee Therapeutics! Die Post-Humira-Ära nimmt Formen an!

AbbVie steht kurz vor einer 10,9 Mrd. USD schweren Übernahme von Apogee Therapeutics, um das Kernsegment Immunologie abzusichern Durch…

AbbVie and Merck Face-Off: Which Pharma Stock Has the Lead?

ABBVs successful transition beyond Humira and growth from newer medicines give it an edge over MRK in this oncology-immunology showdown.…

AbbVies biggest deal since 2019 could land soon

AbbVie (ABBV) is closing in on a deal to buy Apogee Therapeutics for $10.9 billion in cash, according to a…

Medincell shares dive 15% as FY26 loss widens, AbbVie trial delayed

Medincell shares dive 15% as FY26 loss widens, AbbVie trial delayed…

Brokers Suggest Investing in AbbVie (ABBV): Read This Before Placing a Bet

Based on the average brokerage recommendation (ABR), AbbVie (ABBV) should be added to ones portfolio. Wall Street analysts overly optimistic…

AbbVie (ABBV) Rises Higher Than Market: Key Facts

AbbVie (ABBV) closed at $227.73 in the latest trading session, marking a +1.32% move from the prior day.…

AbbVie (ABBV) Ascends While Market Falls: Some Facts to Note

AbbVie (ABBV) closed at $227.23 in the latest trading session, marking a +1.02% move from the prior day.…

AbbVie Gets EU Nod for Aquipta as Acute Treatment for Migraine

ABBV wins EU approval for Aquipta for acute migraine treatment in adults, adding a second approved indication in migraine.…

Johnson & Johnson Hopes to Dethrone AbbVies Biggest Growth Driver. Heres Why Investors Shouldnt Panic

AbbVies shareholders can sleep easy.…

CytomX (CTMX) Q4 2025 Earnings Transcript

Image source: The Motley Fool.DATEMonday, Mar. 16, 2026 at 8 a.m. ETCALL PARTICIPANTSChief Executive Officer and Chairman — Sean McCarthy,…

The S&P 500 Is Expensive, but These 3 Dividend Stocks Still Look Like Bargains

AbbVie, CVS Health, and Verizon Communications are all high-yielding stocks with attractive valuations and robust financials.…

CEO Chat with Steven Quay, MD, PhD, Chairman, President, & CEO of Atossa Therapeutics

NASDAQ: ATOSDavid Bautz, PhD: Welcome to the next episode of our CEO Chat series. My name is David Bautz, and…

AbbVie Inc. (ABBV) Presents at EU Clinical Trial Regulation: Latest Developments and Upcoming Opportunities Transcript

…

AbbVie (ABBV) Up 3.5% Since Last Earnings Report: Can It Continue?

AbbVie (ABBV) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for…

How Did AbbVies Oncology Portfolio Perform in Q1 Despite Headwinds?

ABBVs oncology revenues dip 3% in Q1 as Imbruvica sales slide, though Venclexta, Elahere and Epkinly post solid gains.…

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock…

Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie?

AZN and ABBV both boast strong drug pipelines and growth outlooks, but differences in valuation, dividends and LOE risks set…

How Important Are Skyrizi and Rinvoq to AbbVies Q1 Results?

ABBVs Q1 beat is powered by Skyrizi and Rinvoq, whose strong sales growth offset Humira declines and boosts 2026 guidance.…

AbbVie Inc. (ABBV) Presents at Bank of America Global Healthcare Conference 2026 Transcript

…

Top Stock Reports for NVIDIA, Mastercard & AbbVie

NVIDIA, Mastercard and AbbVie headline Zacks top stock reports, with AI growth, payment trends and drug launches in focus.…

AbbVie Deserves A Higher Multiple

…

CHRS Q1 2026 Earnings Transcript

Image source: The Motley Fool.DATEMonday, May 11, 2026 at 5 p.m. ETCALL PARTICIPANTSChief Executive Officer — Dennis M. LanfearChief Medical…

AbbVies Latest Results Reveal a Trend Investors Shouldnt Overlook

But is the stock a buy on the dip?…

Evolus (EOLS) Q2 2025 Earnings Call Transcript

Image source: The Motley Fool.DATETuesday, August 5, 2025 at 4:30 p.m. ETCALL PARTICIPANTSPresident & Chief Executive Officer — David MoatazediChief…

US FDA declines to approve AbbVie’s wrinkle treatment due to manufacturing concerns (April 23)

US FDA declines to approve AbbVie’s wrinkle treatment due to manufacturing concerns (April 23)…

AbbVie’s Earnings Beat Wall Street’s Estimates. Investors Are Still Worried

…

AbbVie upgraded to ‘Buy’ as growth outlook strengthens despite competition fears

AbbVie upgraded to ‘Buy’ as growth outlook strengthens despite competition fears…

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

AbbVie on Wednesday reported better-than-expected quarterly revenue and profit, fueled by demand for newer immunology drugs Skyrizi and Rinvoq, as…

ABBV Beats on Q1 Earnings & Sales, Raises 26 EPS View

AbbVie tops Q1 estimates on strong Rinvoq and Skyrizi sales, lifts 2026 EPS outlook and gains premarket despite continued Humira…

AbbVies TrenibotE Receives FDA CRL Due to Manufacturing Issues

ABBV gets FDA CRL for TrenibotE tied to manufacturing issues. The company plans a full response in the coming months.…

US FDA rejects AbbVie’s wrinkle treatment due to manufacturing concerns

US FDA rejects AbbVie’s wrinkle treatment due to manufacturing concerns…

AbbVie to build $1.4B North Carolina plant

AbbVie to build $1.4B North Carolina plant…

AbbVie Trades Below 50-Day and 200-Day SMA: How to Play the Stock

AbbVie stock trades below key SMAs, signaling weakness, but strong Skyrizi and Rinvoq growth and a robust pipeline could support…

Thyroid Eye Disease Treatment Market Research Report 2026 Featuring Amgen, Viridian, Novartis, Roche, Sanofi, AbbVie, and Teva with Analyst Recommendations and Forecasts to 2031

Market opportunities in the Thyroid Eye Disease Treatment sector include advancements in therapeutic approaches, rising awareness, improved diagnostics, and expanded…

dpa-AFX ProFeed